IP Management
Drugpatentwatch
DrugPatentWatch is thinkBiotech’s long-running pharmaceutical patent intelligence platform, and the strongest public evidence places it squarely in loss-of-exclusivity and generic-entry decision support rather than generic IP administration. The product combines Orange Book and Purple Book patent links, regulatory protections, patent litigation, pricing, sales, and supplier data into a drug-centric research workflow. The clearest practitioner jobs are fivefold. First, pharma legal, BD, and commercial teams use it when nobody agrees on the real loss-of-exclusivity date because patent terms, exclusivities, settlements, and litigation milestones point in different directions. Second, generic challengers and outside counsel use it to decide whether a Paragraph IV or related entry strategy has a real path through the thicket of secondary patents, manufacturing claims, and prior settlements. Third, analysts use it to monitor patent and litigation changes with daily updates and custom alerts instead of checking FDA, court, and patent sources manually. Fourth, global patent and prior-art style searches matter because the product links active and expired drug patents across 134 countries and highlights expired or abandoned rights. Fifth, the platform is positioned for broader market-entry and competitive-intelligence work, including API sourcing, biosimilar tracking, and market share forecasting. Public pricing is unusually transparent for this niche: starter and professional plans are listed, along with a custom enterprise tier. The tradeoff is that the site is marketing-heavy, the policy pages appear stale, and I did not find public security documentation strong enough to verify enterprise claims beyond SSL, privacy-policy language, and a pricing-page promise of a privacy-centric architecture.
Capabilities
Spans 6 product areas: Intellectual Property Practice, Legal Research, Litigation , Analytics, Data , Visualization.
Workflow Coverage
Based on published feature listings, this tool maps to 3 workflow areas:
- Research & Analysis — Citation Checking
- Document Drafting & Automation
- Filing & Compliance
Workflow mappings derived from published feature lists. Not independently verified.
What We Haven’t Verified
This page was assembled from publicly available information. Feature claims and workflow mappings are based on what the vendor and third-party listings publish — not hands-on testing or practitioner feedback.
Workflows
Based on practitioner evidence, Drugpatentwatch is used in these workflows:
What practitioners struggle with
Real frustrations from legal professionals — the problems Drugpatentwatch addresses (or should address). Sourced from practitioner reviews, Reddit threads, and case studies.
Litigation team monitors 200+ active federal cases and needs instant alerts when opposing counsel files a motion, a judge issues an order, or a deadline shifts — but PACER has no native notification system, so paralegals manually check dockets daily
Patent attorney conducting a prior art search for a client's invention spends 2-3 days manually searching USPTO, EPO, and non-patent literature databases — reading hundreds of abstracts, mapping claims to prior art references, and still worrying they missed something in a Chinese or Japanese patent that wasn't translated. The search costs the client $5,000-15,000 and the attorney still can't guarantee completeness
Brand, generic, or investor team is staring at a drug that matters to the forecast, and everyone has a different answer for when exclusivity really ends because Orange Book patents, regulatory exclusivities, SPCs, settlements, and litigation milestones all point in different directions, so they need one defensible loss-of-exclusivity view before they commit money or change launch plans.
Generic strategy, BD, or outside counsel sees a blockbuster approaching the patent cliff and wants to know whether there is actually a winnable entry path, but the answer is buried across Paragraph IV filings, secondary patents, manufacturing claims, tentative approvals, and old settlements, so they need to find the real white space before they sink money into a doomed challenge or sourcing program.
Where it fits in your workflow
Before Drugpatentwatch
A branded pharma company, generic challenger, investor, or outside counsel needs to answer a go or no-go question about a drug: when exclusivity actually ends, whether a generic path is viable, or what patent and litigation events are likely to change the timing.
After Drugpatentwatch
After DrugPatentWatch surfaces the patent, exclusivity, litigation, pricing, and market-entry picture, teams still decide whether to file or defend a challenge, fund a generic program, adjust launch timing, negotiate a settlement or license, change sourcing strategy, or brief management on revenue at risk.
Integrations & hand-offs
Legal and IP teams use the research to brief regulatory, business development, commercial, supply-chain, and investor stakeholders. Litigation and Paragraph IV signals feed outside-counsel strategy. Alerting and exports hand off into internal watchlists, forecasts, and launch models.
Community Data
Loading practitioner-sourced data…